Press Releases and Blog
Blog
Renewed Congressional Focus On Patent Abuse Touts Proposals to Effectively Lower Prescription Drug Costs, Strengthen Competition in the Market
U.S. Senators Peter Welch (D-VT), Mike Braun (R-IN), and Amy Klobuchar (D-MN) recently introduced legislation that will crack down on drug companies’ patent abuse, specifically patent
ICYMI: 2021 House Oversight Committee Report Concluded Rebates Are Uncorrelated With Drug Prices
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with
ICYMI: Former U.S. Senator Pat Toomey: GOP Can’t Afford to Start 2024 with Giant Health Care Mandates
In case you missed it, former U.S. Senator Pat Toomey (R-PA) warns Republican policymakers against passing unvetted and disastrous policies targeting pharmacy benefits being debated
ICYMI: New Report Underscores That Rebates Have No Correlation With High Drug Prices
In case you missed it, a new report from health policy researcher Alex Brill, founder and CEO of Matrix Global Advisors and former policy director
ICYMI: New Public Employee Policy Research Affirms PBMs Are Essential In Administering Pharmacy Benefits, Public Sector Employers Satisfied With Their Pharmacy Benefit Companies
In case you missed it, the National Institute for Public Employee Health Care Policy recently released a report, “How Public Sector Health Care Purchasers Are
ICYMI: Former Senator Pat Toomey Cautions Congress Against Proposals Targeting Pharmacy Benefit Companies
In case you missed it, WTOP’s Mitchell Miller spoke with former U.S. Senator Pat Toomey (R-PA) about the current health care debate in Congress in
Press Releases
PCMA Statement on Senate Finance Committee Vote
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s vote in the Senate Finance Committee to advance legislation impacting
PCMA Statement on CMS’ Proposal to Promote the Use of Biosimilars in Medicare Part D
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) supports the Centers for Medicare and Medicaid Services’ (CMS) proposal to promote the use of biosimilars
Senate Finance Committee Bill Will Cost Taxpayers and is a $10 Billion Giveaway to Big Pharma
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today on legislation introduced by Senate Finance Committee members: The just-released Senate
National Bureau of Economic Research Working Paper: “Delinking” Proposals that Restrict PBM Incentives to Secure Rx Savings Will Increase Drug Prices and Provide $10B Giveaway for Big Pharma
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on a new research paper, “Ending Pay for PBM Performance: Consequences
PCMA Statement on Legislation Introduced in the House of Representatives
(Washington, D.C.) — PCMA issued the following statement on legislation introduced in the House of Representatives: Legislation introduced in U.S. House of Representatives targeting pharmacy
PCMA Statement on the Tenth Circuit’s Decision in PCMA v. Mulready
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) applauds the recent ruling by the U.S. Court of Appeals for the Tenth Circuit in PCMA
ICYMI: Employers Choose Spread Pricing for a Reason
Millions of Patients Impacted if Option to Use Spread Pricing is Taken Away Pharmacy benefit companies offer employers and health plans flexibility when they’re designing
ICYMI: JAMA Article Affirms Misguided Policies Targeting Pharmacy Benefit Companies Would Weaken Negotiating Power Against Big Pharma, Undercut Savings
A team of professors from Johns Hopkins University, Georgetown Law School, and Utah University College of Pharmacy published in the JAMA Health Forum a paper,
Current And Former Policymakers, Experts Agree Anti-PBM Bills Restrict Free Market, Would Do Nothing To Lower Rx Drug Costs
As Congress considers anti-PBM legislation in the new year, it is important lawmakers are aware that allowing the government to dictate the winners and losers
ICYMI: PCMA Rx Research Corner: In Their Pharmacy Benefit Company Relationships, Employers Have Choice, Flexibility, And The Final Say
In case you missed it, a new PCMA Rx Research Corner blog highlighted the value employers find in their pharmacy benefit company relationships. As Congress
Anti-PBM Bills Would Take Away the Choice and Flexibility Employers Say They Value
Employers overwhelmingly say they’re satisfied with their PBM, describe PBM contracts as “transparent,” and value a wide range of choices from their PBMs A recent
ICYMI: Policymakers And Expert Panel Highlight Negative Consequences Of Misguided Policies Targeting Pharmacy Benefits
In case you missed it, last week’s RealClearPolitics’ virtual event, “The Consequences of Targeting Pharmacy Benefits,” featured policymakers and expert voices exploring the potential negative
Reminder: Conservative Thought Leaders And GOP Lawmakers Oppose Anti-PBM Government Mandates
The U.S. House of Representatives is preparing a suspension vote on the Lower Costs, More Transparency Act, which includes many of the controversial, overreaching proposals
Former Representative Altmire Joins Former U.S. Senator Pat Toomey In Cautioning Lawmakers Against Passing Proposals Targeting Pharmacy Benefits
In case you missed it, Jason Altmire, former Democratic three-term U.S. Representative from Pennsylvania and current adjunct professor at Texas Tech University, explains why so-called
ICYMI: JC Scott In RealClearHealth: Amid Rising Health Care Premiums, Misguided Legislation Would Raise Costs Even Higher
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association, discusses how recent proposals being considered by Congress targeting
ICYMI: Former U.S. Senator Pat Toomey: Before Targeting PBMs, Republicans Should Consider The Unintended Consequences
In case you missed it, Pat Toomey, former U.S. Senator from Pennsylvania, cautioned lawmakers against legislation targeting pharmacy benefit companies and policies that meddle with